论文部分内容阅读
目的:观察培美曲塞联合铂类药治疗晚期复发性肺癌的临床疗效。方法:患者采用培美曲塞联合顺铂治疗,第一天静脉滴注培美曲塞,500mg/m2;第一天到第三天静脉滴注顺铂,25mg/m2,3周为一个疗程。结果:完全缓解2例(3.70%),部分缓解8例(14.81%),稳定21例(38.89%),进展20例(37.04%);有效率为18.52%,疾病控制率为57.41%。结论:培美曲塞与顺铂联合治疗晚期复发性非小细胞肺癌的疗效较好,患者不良反应少且易处理,患者治疗的耐受性良好,临床适用于特质虚弱的患者,可显著提高患者治疗的生活质量,值得临床推广。
Objective: To observe the clinical efficacy of pemetrexed combined with platinum drugs in the treatment of advanced recurrent lung cancer. Methods: Patients were treated with pemetrexed combined with cisplatin, the first day intravenous pemetrexed, 500mg / m2; the first day to the third day of intravenous cisplatin, 25mg / m2, a course of 3 weeks . Results: Complete remission was achieved in 2 cases (3.70%), partial remission in 8 cases (14.81%), stabilization in 21 cases (38.89%) and progression in 20 cases (37.04%). The effective rate was 18.52% and the disease control rate was 57.41%. Conclusion: The combination of pemetrexed and cisplatin in the treatment of advanced recurrent non-small cell lung cancer has better curative effect, less side effects and easy treatment, and the patient’s treatment is well tolerated. It is clinically applicable to patients with idiopathic weakness and can be significantly improved The quality of life of patients treated, it is worth clinical promotion.